Sedana Medical submits market approval application for the drug Sedaconda
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has submitted an application for market approval for the drug candidate Sedaconda (isoflurane), formerly known as IsoConDa, for inhaled sedation in intensive care. The application has been submitted to the German Medicines Agency BfArM and a number of other European Medicines Agencies through a so-called DCP procedure.The application is the starting point of the review process of Sedaconda in 15 of the EU member states, including Norway. If all goes well, Sedana Medical expects an approval in the second half of